Forte Biosciences Inc
FBRX
Company Profile
Business description
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
Contact
3060 Pegasus Park Drive
Building 6
DallasTX75247
USAT: +1 310 618-6994
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
Why earnings growth might be more important when assessing frothy market conditions.
stocks
Are negative AI narratives holding this ASX share back?
This company is unlikely to be disrupted by AI
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,022.30 | 13.00 | -0.14% |
| CAC 40 | 8,367.33 | 17.54 | -0.21% |
| DAX 40 | 24,626.89 | 44.33 | -0.18% |
| Dow JONES (US) | 52,182.74 | 306.63 | 0.59% |
| FTSE 100 | 10,484.22 | 23.80 | -0.23% |
| HKSE | 22,752.96 | 273.72 | -1.19% |
| NASDAQ | 25,820.14 | 522.53 | 2.07% |
| Nikkei 225 | 70,497.94 | 1,029.83 | 1.48% |
| NZX 50 Index | 13,638.71 | 93.15 | 0.69% |
| S&P 500 | 7,440.43 | 86.41 | 1.18% |
| S&P/ASX 200 | 8,818.80 | 12.70 | -0.14% |
| SSE Composite Index | 4,082.13 | 8.23 | 0.20% |